Biocon acquired Eywa's OSD facility, investing $30M to produce 2 billion tablets annually for global distribution.

• The plant strengthens supply chain resilience, ensuring tablet delivery across the United States and international markets.
• Biocon's CEO emphasizes proximity to patients, enhancing efficient access to affordable, high-quality therapies worldwide.
• The facility supports Biocon's mission, diversifying manufacturing, expanding its footprint, and accelerating pipeline product commercialization globally.